Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ISHL HL Update 2021 | 1st-line therapies in Hodgkin lymphoma

Paul Jan Bröckelmann • 11 Mar 2021
ISHL HL Update 2021
Hodgkin Lymphoma Lymphoma Antibodies Brentuximab vedotin
HD21

Paul Jan Bröckelmann, MD, University Hospital of Cologne, Cologne, Germany, discusses innovative 1st-line therapies currently being evaluated in patients with Hodgkin lymphoma, the perspective of the German Hodgkin Study Group, including the ongoing HD21 trial (NCT02661503), as well as elderly patients with Hodgkin lymphoma, who represent an area of unmet need. This interview took place at the Update on Hodgkin Lymphoma 2021, a Virtual ISHL event.

More from Paul Jan Bröckelmann

The growing role of anti-PD1 inhibitors in the frontline treatment of HL
2:32
The growing role of anti-PD1 inhibitors in the frontline treatment of HL
Paul Jan Bröckelmann • 17 Oct 2022
The importance of individualizing treatment approaches in HL to improve patient outcomes
2:04
The importance of individualizing treatment approaches in HL to improve patient outcomes
Paul Jan Bröckelmann • 17 Oct 2022
Using Hodgkin lymphoma as a model for immuno-oncologic therapeutic approaches in other lymphomas
2:27
Using Hodgkin lymphoma as a model for immuno-oncologic therapeutic approaches in other lymphomas
Paul Jan Bröckelmann • 17 Oct 2022
Recent clinical developments in the treatment landscape for older patients with HL
2:17
Recent clinical developments in the treatment landscape for older patients with HL
Paul Jan Bröckelmann • 17 Oct 2022

Related Videos

The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Paul Jan Bröckelmann • 6 Dec 2025
Impact of bridging therapy on efficacy of CD19 CAR T-cell therapy in DLBCL
2:10
Impact of bridging therapy on efficacy of CD19 CAR T-cell therapy in DLBCL
Paul Jan Bröckelmann • 8 Dec 2025
Phase II results of rituximab and epcoritamab as 1L therapy for patients with high-tumor-burden FL
2:42
Phase II results of rituximab and epcoritamab as 1L therapy for patients with high-tumor-burden FL
Paul Jan Bröckelmann • 8 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Paul Jan Bröckelmann • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals